ABSTRACT-E4177, 3-[(2'-carboxybiphenyl-4-yl)methyl]-2-cyclopropyl-7-methyl-3H-imidazo [4, 5 b]pyridine, was characterized by in vitro autoradiography and by examining functional antagonism upon angiotensin II (Ang II)-induced contraction of isolated vessels. In rat adrenal cortex and liver, E4177 com petitively inhibited the specific binding of 125I-[Sar',Ile8]Ang II, with IC50 being (5.2± 1.0) x 10-8 M for the adrenal cortex and (1.2±0.3) x 10-7 M for the liver. These IC50 values were similar to those for losartan, which showed an IC50 of (6.0±0.9) x 10-8 M for the adrenal cortex and (1.3 ±0.5) x 10-7 M for the liver. In contrast, E4177 and losartan had little effect on the binding to rat adrenal medulla where AT2-receptors predominate. These results indicate that E4177 is AT,-specific as is losartan. E4177 and losartan competitive ly antagonized the Ang II-induced contraction of human and rabbit arterial strips without any agonistic ac tion. The obtained IC50 values indicated that E4177 was twice as potent as losartan in human arteries and three times more so in rabbit aortic strips. Responses to norepinephrine, serotonin, histamine or KCl were not affected by E4177. In addition, E4177 (10-5 M) had no effect on angiotensin-converting enzyme activity. These data indicate that E4177 is a potent AT, Ang II-receptor antagonist that may be clinically useful for the treatment of cardiovascular diseases such as hypertension.
The renin-angiotensin system (RAS) plays a critical role in blood pressure regulation and fluid and electrolytes homeostasis through angiotensin II (Ang II), an active principle of the system (1, 2) . In addition to such well known actions of Ang II, it is assumed that Ang II may have diverse actions (3) . To explore further the potential role of Ang II, an agent that interrupts the formation of Ang II or its action at the receptor sites would be an essen tial tool. Angiotensin-converting enzyme (ACE) inhibi tors have been successfully used as such; they are excel lent therapeutics for hypertension and heart failure, and they have served to introduce the concept of "tissue" RAS (4) . Recent studies suggested that ACE inhibitors prevent the neointimal thickening after intimal injury (5) and in atherosclerotic vessels (6, 7) , indicating the involvement of Ang II in such trophic disorders. However, since ACE acts on many substrates other than Ang I such as brady kinin, substance P and enkephalins, the actions of ACE inhibitors are not completely specific. In fact, antihyper trophic effects of ACE inhibitors on balloon-injured blood vessels have been claimed to involve factors other than Ang II (8, 9) . Furthermore, there are Ang 11-generat ing enzyme systems other than ACE in dog and primate blood vessels (10) and human heart (11), indicating persist ent Ang II generation even after ACE inhibition. In view of these limitations of ACE inhibitors, specific Ang II receptor antagonist should be advantageous for evaluat ing the pathophysiological meanings of the angiotensin system.
Losartan (also called DuP753) is a breakthrough novel Ang II-receptor antagonist which is non-peptide and de void of any agonist activity (12) . Following the develop ment of new classes of Ang II-receptor antagonists, two distinct subtypes of Ang II receptors have been identified. A standard nomenclature for Ang II receptor subtypes has been proposed, in which the Ang II receptors inhibit ed by losartan, a prototypic AT,-receptor antagonist, are designated AT,-receptors; and those inhibited by PD 123177, PD 123319, or CGP42112A are designated as AT2-receptors (13) . AT,-receptors are believed to be responsible for known biological actions of Ang II but the function of AT2-receptors is not clear at present (3) .
In the present study, we describe the in vitro pharma cological properties of a chemically novel, non-peptide Ang II-receptor antagonist, E4177 (Fig. 1 ). Our findings indicate that this compound is an AT,-selective and com petitive antagonist of Ang II. 
MATERIALS AND METHODS
Binding assay for Ang II receptors in rat adrenal gland and liver Ang II receptors were labelled by in vitro auto radiography by using 125I-[Sar',Ile8]Ang II ligand as described elsewhere (14) . Male Wistar rats (300-350g) were decapitated, and then their adrenal glands and liver were removed quickly, frozen in isopentane-dry ice ( 401C) and stored at 801C. Serial 20-pm sections were cut on a cryostat, thaw-mounted onto gelatin-coated slides and dried in a desiccator under reduced pressure overnight at 4C. Sections were then preincubated in 10 mM sodium phosphate buffer, pH 7.4, containing 150 mM NaCl, 5 mM Na2EDTA, 0.1% NaN3, and 0.2% bo vine serum albumin (buffer A) for 15 min at room temper ature. Sections were then incubated in a fresh volume of buffer A containing 0.1 pCi (-50 pM) of 125I-[Sar',Ile8] Ang II for 2 hr at room temperature. After incubation, sections were washed by four successive 1 min-washes in ice-cold buffer A without bovine serum albumin. Then the sections were dried under a stream of cold air and ap posed to Fuji RX-X ray films in a cassette and exposed for 1.5 days for the adrenal glands or 4 days for the liver. After development of the films, the autoradiograms were 
Effect of E4177 on ACE activity
To examine if E4177 affects ACE activity in vitro, bea gle lung ACE extracts were incubated with or without 10-5 M E4177 using Hip-His-Leu as a substrate. Hippuric acid liberated during the incubations was measured by high-performance liquid chromatography to quantitate the ACE activity (15) . Trandolaprilat (16), a highly po tent ACE inhibitor, was used as a positive control.
Effect of E4177 on angiotensin-induced contraction in isolated blood vessels
The effect of E4177 on vascular Ang II receptors was ex amined in human gastroepiploic artery and rabbit aorta. Gastroepiploic artery specimens were isolated from omen ta which were attached to the resected stomachs from 24 patients, aged 24-75 years, by operation for the treat ment of gastric cancer or gastric ulcer. Descending tho racic aortae were removed from male Japanese White rab bits (3.1-3.3 kg; Keari Co., Osaka) under sodium pento barbital anesthesia (60 mg/kg). Human gastroepiploic ar teries and rabbit aortae were cut into helical strips 2 to 2.5-mm-wide and 20-mm-long and 3.0-mm-wide and 20 mm-long, respectively. These strips were mounted in a tis sue bath containing Tyrode's solution composed of 137 mM NaCl, 2.7 mM KC1, 1.8 mM CaC12, 1.1 MM MgC12, 0.42 mM NaH2PO4, 12 mM NaHCO3 and 5.7 mM glu cose. The Tyrode's solution was kept at 37C and gassed continuously with 5010 CO2 in oxygen. The initial resting tension was set at 1.5 g for human arterial strips and 2.0 g for rabbit aortic strips. Isometric tension signals were detected with a force-displacement transducer (Nihon Kohden, Tokyo), amplified and displayed on a chart re corder (Pantos, Kyoto). After an equilibration period of 90-120 min, the strips were stimulated by adding 30 mM KC1 to which the response of each strip served as the refer ence for agonist-induced contraction of the correspond ing strip. The control cumulative concentration-response curve for Ang II (10-10-3 x 10-' M) was first obtained. Following this, the tissues were washed 5 times over a 1-hr period, and then various concentrations of antagonists were added and allowed 20-min contact prior to the addi tion of agonists. To measure the potency of E4177 and losartan, the pA2 values (negative logarithms of dissocia tion constant) were determined according to the methods described by Arunlakshana and Schild (17) . To determine the IC50 values, another series of experiments were carried out where the inhibition of 20 nM Ang II-induced responses was assessed with various concentrations of Ang II antagonists.
Verification of the specificity of E4177
To test the specificity of E4177, contractile responses to KC1 (30 mM), norepinephrine (10-7 3 x 10-'M), and serotonin (3 x 10'-10-5 M) were examined before and after a 20-min incubation with 1 1 M E4177. Whether Ang II antagonists affect the relaxations induced by hista mine (10-7-10-5 M) was also examined in human arter ies precontracted with 30 mM KC1.
Drugs
E4177 and losartan were synthesized at Tsukuba Research Laboratories, Eisai Pharmaceutical Co., Ltd. Trandolaprilat was a gift from Nippon Roussel (Tokyo). 
RESULTS
Interaction of E4177 and losartan with Ang II receptors evaluated by in vitro autoradiography The ability of E4177 to interact with Ang II receptors in rat adrenal glands and livers was evaluated. Because non specific binding determined in the presence of 0.5 tiM un labeled [Sar',I1e8]Ang II was very weak and no visible im age was observed on the X-ray films, the data presented in dicated the specific binding. In rat adrenal glands, E4177 potently inhibited the ligand binding to the cortex where AT,-receptors are known to be predominant. In contrast, E4177 only slightly inhibited the binding to the medulla where AT2-receptors are known to be predominant (Fig.  2) . In the rat liver, which exclusively contains AT,-recep tors, E4177 inhibited the binding potently. Similar results were observed with losartan, an established selective AT, receptor antagonist, both in the adrenal glands and livers. All the above findings indicated that E4177 was selective towards AT,-receptors.
Interaction with Ang II receptors were further evaluat ed by competitive binding experiments. As shown in Fig.  3A , [Sar',Ile8]Ang II displayed high affinity for the Ang II receptors in the adrenal cortex with an IC50 of 1.6 x 10-9 M. E4177 inhibited the binding in a biphasic manner with an IC50 of (5.2± 1.0) x 10-8 M for the AT,-sites and > 10-5 M for the AT2-sites. IC50 values of losartan were (6.0±0.9) x 10-8 M for the AT,-sites and > 10-5 M for the AT2-sites, being very similar to those of E4177. In rat adrenal medulla, unlabelled [Sar',Ile8]Ang II inhibited the binding of radioligand in a monophasic manner as in the adrenal cortex, whereas neither E4177 nor losartan showed substantial inhibition of the binding, indicating again that E4177 was selective for AT,-receptors (Fig.  3B) . In the rat liver where AT,-receptors are exclusively recognized, both E4177 and losartan were potent in com peting with '251-[sar',Ile8]Ang II with IC50s of (1.2±0.3) X 10-7 M and (1.3±0.5) x 10-7 M, respectively (Fig. 4) .
Effect of E41 77 on angiotensin-converting enzyme activity
The effect of E4177 and the ACE inhibitor trandolapri lat on ACE activity was investigated with beagle lung ACE extract. Trandolaprilat (1 pM) completely inhibited ACE activity, whereas E4177 (10 pM) did not exhibit sub stantial inhibition on ACE (data not shown). Antagonism to Ang II-induced contractile responses E4177 competitively antagonized the contractions in duced by Ang II in isolated rabbit aortae. With increasing concentrations of E4177 (3 x 10-9-3 x 10-8 M), the con centration-contractile response curve to Ang II was characterized by a parallel rightward shift (Fig. 5) . Schild analysis of the data gave a pA2 value of 8.8±0.1 and a slope of 1.1 ± 0.1, indicating that the antagonism shown by E4177 was competitive. The antagonism produced by losartan (10-8 3 x 10-8 M) was also characterized by a rightward shift of the Ang II concentration-contractile response curve, and the pA2 value and slope were estimat ed as 8.3±0.1 and 1.2±0.1, respectively. Maximal con tractile responses were well maintained even at the highest concentrations of E4177 and losartan. This indicates the effects of these compounds were completely reversible.
In both human gastroepiploic artery and rabbit aorta, E4177 inhibited the contractile responses to 20 nM Ang II in a dose-dependent manner, with IC50 values of (4.3± 0.7) x 10-9 M (n= 13) for human artery and (5.3 ± 1.8) x 10-9 M (n=5) for rabbit aorta. On the other hand, IC50 values obtained with losartan were (7.8 ± 0.9) x 10-9 M (n=11) in human artery and (1.6±0.2) x 10-8 M (n=5) in rabbit aorta (Fig. 6, A and B) .
Specificity of the antagonism E4177 (10-6 M) did not significantly affect the concen tration-response curve to norepinephrine (10-'-3 x 10-5 M) or serotonin (3 x 10-8-10-5 M) (data not shown). The concentration of E4177 employed was more than sufficient to antagonize Ang II-induced vascular contrac tion in human gastroepiploic artery. A range of concentra tions of E4177 (10-9-10-4 M) did not alter the contrac tile response to 30 mM KC1 (data not shown). Relaxing responses to histamine in human gastroepiploic artery were not affected by 10-7-10-6 M of E4177 (data not shown). In the absence of Ang II, E4177 did not affect the basal resting tension of these tissues at any of the concen trations examined.
DISCUSSION
In the present study, we characterized the in vitro pharmacological properties of a chemically novel Ang II receptor antagonist, E4177.
AT,-receptors predominate in rat adrenal cortex, whereas AT2-receptors are predominant in the adrenal medulla (12, 18) . E4177 inhibited 125I-[Sar',Ile8]Ang II binding to the cortex in a biphasic manner, and even at the highest concentration of E4177, about 20% of the binding still persisted. In the medulla, E4177 had little effect on the radioligand binding. These data indicate that E4177 binds selectively to AT,-receptors. Consistent with this, E4177 blocked 1251-[Sar',Ile8]Ang II binding in a monophasic manner to rat liver which contains only AT, receptors (12, 18) . Our data on the effects of losartan on '251 -[Sar' ,Ile8]Ang II binding in the adrenal glands and liver agreed well with previous observations (14, 19) . In the competitive binding experiments, E4177 was as potent as losartan, as indicated by the similarity in their IC50 values.
E4177, as well as losartan, exhibited a reversible and competitive antagonism, as shown by the parallel shift of the concentration-response curve produced in isolated rabbit aortae without affecting the maximal responses.
The resting tension was not affected by E4177 at any of the concentrations tested in either human gastroepiploic artery or rabbit aortae. These findings indicate that E4177 has no agonistic effect.
E4177 is specific to Ang II receptors; it did not affect the contractile responses evoked by norepinephrine, serotonin, or KC1. Furthermore, E4177 had no effect on the relaxing responses to histamine in human arteries precontracted with KC1. ACE activity was not affected by E4177 at a concentration as high as 10-5 M, which was sufficient to fully antagonize the contractions induced by Ang II.
In the experiment using isolated vessels, since E4177 was found to be more potent than losartan in antagoniz ing Ang II-induced contraction, it may be expected that the blood pressure-lowering effect of E4177 is also more potent than that of losartan. This possibility is supported by our in vivo study, which also indicates the oral bio availability of E4177 (K. Ishii et al., to be published else where).
In conclusion, the present data obtained from in vitro binding studies and isolated vascular contraction assay demonstrate that E4177 is a competitive and reversible AT,-specific antagonist without agonistic activity. This newly developed agent has an in vitro potency compara ble to or slightly higher than the known AT,-antagonist losartan. These properties suggest that E4177 would be useful for exploring the as yet undefined role of Ang II in both normal and disease states as well as being useful for treating cardiovascular diseases in which Ang II is patho genically involved.
